FDA clarification that OTC ephedrine proposal exempts ephedra requested in comments.
This article was originally published in The Tan Sheet
Executive Summary
FDA CLARIFICATION THAT OTC EPHEDRINE PROPOSAL DOES NOT EXTEND TO EPHEDRA REQUESTED in Sept. 27 comments submitted to the agency by a group involved in the marketing of ephedra herb tea. "Because an indiscriminate determination that all ephedrine is not GRAS would adversely affect the joint commenters' economic interests and their opportunity to continue marketing and consuming ephedra herb tea," the comments state, "they...feel compelled to request that the agency make clear that it does not intend for its final rule to affect ephedra herb food or dietary supplements."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning